ViiV Healthcare Announces Phase II Study Results for First Two Drug, Long-acting Injectable Regimen for HIV-1 Treatment
London (ots/PRNewswire) - 32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented ...